Medical News

notebook_studie_výzkum_laptop_vzdělávání

Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker

2. 2. 2020 Source: Prostate Health Index

The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of prostate-specific antigen (PSA), free PSA (fPSA), and the isoform [-2]proPSA (p2PSA). Its use in prostate cancer diagnostics can reduce the number of unnecessary prostate biopsies compared to determining PSA alone. A recently published Czech study assessed the utility of PHI in evaluating the aggressiveness of prostate cancer. The study compared PHI values with the results of preoperative biopsy and postoperative prostate histology in men indicated for…

Cardiovascular Benefit of SGLT2 Inhibitors Confirmed

The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a...

31. 1. 2020 Source: Diabetes

Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?

Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women. However, women in the USA who are indicated for this treatment have historically taken it less…

31. 1. 2020 Source: Cardiovascular Risks

Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients

Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis…

28. 1. 2020 Source: Thromboprophylaxis

Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity

Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often…

28. 1. 2020 Source: Thromboprophylaxis

Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients…

27. 1. 2020 Source: Non-Hodgkin Lymphomas and CLL

Kadcyla in a New Indication –⁠ Adjuvant Therapy for Early HER2+ Breast Cancer

In December, the European Commission approved the expansion of the indication for Roche's medicinal product Kadcyla, which contains the active substance trastuzumab emtansine. This expansion makes…

23. 1. 2020 Source: Breast Carcinoma

Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist −⁠ NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of…

20. 1. 2020 Source: Antiemetic Therapy

Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of…

20. 1. 2020 Source: Antiemetic Therapy

Impact of Oral Antidiabetics on Heart Failure

Diabetes mellitus is primarily perceived as a risk factor for ischemic heart disease and general atherosclerotic complications. However, an equally significant problem is the association between diabetes...

19. 1. 2020 Source: Diabetes

1 … 160 161 162 163 164

Back Filter by speciality

Remove filters